La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Chemomab Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Chemomab Therapeutics..

Chemomab Therapeutics (NASDAQ:CMMB) Azioni, Catena delle Opzioni

Chemomab Therapeutics

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics Ltd

Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is making waves in the semiconductor industry with a $65 billion investment in Arizona, bolstering the U.S.&#8217;s advanced chipmaking capabilities. The U.S. will likely secure the second-largest global market share in advanced semiconductor production by 2027, increasing its share from 9% to 21%, the Taipei Times <a target="_blank" href="https://www.taipeitimes.com/News/biz/archives/2024/11/25/2003827422" rel="noreferrer noopener">cites</a> from a TrendForce Corp report.
Taiwan Semiconductor is developing cutting-edge 3nm, 2nm, and even 1.4nm processes, with mass production of 3nm chips already underway in Tainan, Taiwan.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42168608/nvidias-fugatto-new-ai-model-lets-you-create-sounds-never-heard-before" rel="noreferrer noopener">Nvidia Unveils Fugatto: AI Tool That Transforms Sound Creation For Music, Ads, And Gaming</a>
Two advanced fabs in Arizona will begin production in 2024 and 2028, focusing on 4nm and 3nm processes, respectively. A third fab using 2nm or more advanced technology is expected by 2030.
Taiwan, however, will likely see its share of advanced integrated circuit (IC) processes decline from 71% to 54% by 2027. Despite this, Taiwan will maintain its position as the global leader, per the report.
South Korea will likely experience a dip, dropping from 11% to 9%, relegating it to the third spot globally.
The U.S. government&#8217;s focus on semiconductor self-sufficiency grows as global competition intensifies. Taiwan Semiconductor bagged up to <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" rel="noreferrer noopener">$6.6 billion in U.S. subsidies</a> and $5 billion in proposed loans to build advanced chip plants in Arizona.
A Boston Consulting Group report estimates that U.S. semiconductor manufacturing capacity could triple by 2032, driven by policies like the CHIPS Act. U.S. capital expenditure on semiconductors will likely constitute 28% of the global total between 2025 and 2032.
Taiwan Semiconductor is ramping up <a target="_blank" href="https://www.benzinga.com/24/11/42116366/taiwan-semiconductor-plans-new-factories-annually-boosting-domestic-chip-production" rel="noreferrer noopener">domestic and global expansion efforts</a>. Over the next decade, the company plans to construct new factories annually in Taiwan, with sites in Kaohsiung, Tainan, and Taichung.
The contract chipmaker is also advancing its international projects, including a second facility in Japan&#8217;s Kumamoto region set to begin construction in 2025 and advanced plants in Arizona and Dresden. The company continues to innovate in advanced packaging technologies like CoWoS and SoIC to stay ahead in the semiconductor market.
Taiwan Semiconductor forecasts record capital expenditures between $34 billion and $38 billion to support its growth in 2025.
Advanced Micro Devices, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) has recently tapped Taiwan Semiconductor to foray into the <a target="_blank" href="https://www.benzinga.com/media/24/11/42168509/amd-teams-up-with-taiwan-semi-to-take-on-samsung-in-smartphone-market" rel="noreferrer noopener">smartphone market, leveraging</a> the chipmaker&#8217;s 3nm process to target Samsung&#8217;s flagship models.
Taiwan Semiconductor stock surged over 82% year-to-date.
Price Action: TSM stock is down 0.15% at $184.80 premarket at last check Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42171519/snowflake-elastic-poised-for-ai-revolution-gains-analyst-upgrades-the-stocks" target="_blank" rel="noreferrer noopener">Snowflake, Elastic Poised For AI Revolution Gains, Analyst Upgrades The Stocks</a></li>
</ul>
Image via Shutterstock.

Equities

News

Tech

Media

Taiwan Semi's Growth Fuels US Rise To Second In Chipmaking: Report

Matt Garth will depart as chief financial officer on December 31, 2024. Mark Scheiwer, who has served as VP and treasurer since December 2022, will become interim CFO and chief accounting officer on January 1, 2025. Garth, who also was chief administrative officer, will help facilitate a seamless transition during the time leading up to January 1. Scheiwer has more than 13 years of experience in a wide range of finance leadership roles at ScottsMiracle-Gro. The Company will conduct a search for a permanent CFO with the assistance of an executive search firm that is expected to consider internal and external candidates.

ScottsMiracle-Gro Announces CFO Matt Garth's Departure, Names Mark Scheiwer Interim CFO

VinFast Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 14.81 percent increase over losses of $(0.27) per share from the same period last year. The company reported quarterly sales of $512.00 million which missed the analyst consensus estimate of $732.16 million by 30.07 percent. This is a 49.42 percent increase over sales of $342.66 million the same period last year.

Earnings

VinFast Auto Q3 EPS $(0.23), Inline, Sales $512.00M Miss $732.16M Estimate

American astrophysicist Neil deGrasse Tyson <a href="https://www.benzinga.com/news/24/10/41546631/neil-degrasse-tyson-calls-elon-musks-mars-mission-a-space-frontier-days-after-his-comments-on-spacex">dismissed</a> SpaceX CEO Elon Musk&#8216;s ambitions to send people to Mars, saying that unless there is a push caused by a shift in geopolitics, it will not be possible as a pure exploration project.
What Happened: &#8220;I have strong views on that. My read of the history of space exploration is such that we do big, expensive things only when it&#8217;s geopolitically expedient, such as we feel threatened by an enemy,&#8221; Tyson said in an <a href="https://www.youtube.com/watch?v=WMzgXHhKarY">interview</a> with Bill Maher. 
The trip to Mars won&#8217;t happen because Musk believes it&#8217;s the next big thing to do, Tyson said, while adding that it would be difficult to gain investment for the Starship project given its high costs and low return on investment. 
&#8220;For him to just say, let&#8217;s go to Mars because it&#8217;s the next thing to do. What is that venture capitalist meeting look like? &#8216;So, Elon, what do you want to do?&#8217; &#8216;I want to go to Mars?&#8217; &#8216;How much will it cost?&#8217; &#8216;$1 trillion.&#8217; &#8216;Is it safe?&#8217; &#8216;No. People will probably die.&#8217; &#8216;What&#8217;s the return on the investment?&#8217; &#8216;Nothing.&#8217; That&#8217;s a five-minute meeting. And it doesn&#8217;t happen,&#8221; he said.
The U.S. will get people to Mars only if there is a geopolitical push like a memo from China that it is planning to put up a military base on Mars, according to Tyson. In that case, the U.S. will aim to get to Mars in ten months and NASA will get the spacecraft from SpaceX for the purpose, he said. 
&#8220;So I don&#8217;t see it happening until governments judge that it&#8217;s geopolitically in our interest,&#8221; Tyson said. &#8220;I got nothing against Mars.&#8221;
According to Tyson, instead of developing Mars to be liveable once Earth becomes unlivable, it would be better to invest in Earth itself.
Why It Matters: Musk, meanwhile, dismissed Tyson. 
&#8220;Wow, they really don&#8217;t get it. Mars is critical to the long-term survival of consciousness. Also, I&#8217;m not going to ask any venture capitalists for money. I realize that it makes no sense as an investment. That&#8217;s why I&#8217;m gathering resources,&#8221; he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Wow, they really don't get it. Mars is critical to the long-term survival of consciousness. Also, I'm not going to ask any venture capitalists for money. I realize that it makes no sense as an investment. That's why I'm gathering resources. <a href="https://t.co/XVCpHKlusD">https://t.co/XVCpHKlusD</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1860322925783445956?ref_src=twsrc%5Etfw">November 23, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Musk has previously said that SpaceX&#8217;s satellite internet segment called Starlink will fund his vision to travel to Mars aboard the company&#8217;s Starship launch vehicle.
The Starship launch vehicle is currently in the development and testing phase. The company has conducted six test flights of the vehicle to date but without a payload. 
"…I would not be surprised if we fly 400 Starship launches in the next four years,&#8221; SpaceX President and COO&nbsp;Gwynne Shotwell&nbsp;<a href="https://www.benzinga.com/general/space/24/11/42105704/spacex-ceo-elon-musk-reveals-technical-glitch-that-led-company-to-drop-key-objective-of-starships-6th-test-flight" target="_blank" rel="noreferrer noopener">said at the Baron Investment Conference</a>&nbsp;in New York earlier this month.
SpaceX is a privately held company. Unlike Musk's publicly held EV company Tesla, SpaceX&nbsp;<a href="https://www.benzinga.com/24/11/42022150/spacex-to-launch-tender-offer-valuing-company-at-over-250-billion-report" target="_blank" rel="noreferrer noopener">does not divulge its financials</a>&nbsp;periodically. Shotwell said at the conference that the company will make "some money" on Starlink this year.
"We are going to make some money on Starlink this year. But ultimately I think Starship will be the thing that takes us over the top as one of the most valuable companies," she said.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/space/24/11/42183996/faa-invites-comments-on-increasing-spacexs-starship-launches-by-5x-to-25-next-year">FAA Invites Comments On Increasing SpaceX&#8217;s Starship Launches By 5X To 25 Next Year</a></li>
</ul>
Photos courtesy: Wikimedia and Shutterstock

SPACE

TSLA

Astrophysicist Neil deGrasse Tyson Dismisses Elon Musk's Mars Vision: SpaceX CEO Hits Back, Says 'They Really Don't Get It'

UBS analyst Thomas Wadewitz assumes JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) with a Sell rating and announces Price Target of $5.

Price Target

Initiation

Analyst Ratings

JBLU

UBS Assumes JetBlue Airways at Sell, Announces Price Target of $5

<ul>
<li>AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint)</li>
<li>Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ)</li>
<li>Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C)</li>
<li>Cataplexy response (≥50% improvement) achieved by 72% of patients at 1 month and 82% at 6 months</li>
<li>Improvement in excessive daytime sleepiness (EDS), assessed by the CGI-C, achieved by 84% of patients at 1 month and 78% at 6 months</li>
<li>Improvement in narcolepsy overall, assessed by the CGI-C, achieved by 90% of patients at 1 month and 90% at 6 months</li>
<li>Well-tolerated with long-term safety profile consistent with previously completed trials and no new safety signals detected</li>
<li>NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Axsome The</li>
</ul>

AXSM

Axsome Therapeutics Reveals AXS-12 Meets Primary Endpoint In ENCORE Long-Term Phase 3 Trial In Narcolepsy

UBS analyst Thomas Wadewitz assumes Delta Air Lines (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) with a Buy rating and announces Price Target of $88.

UBS Assumes Delta Air Lines at Buy, Announces Price Target of $88

Needham analyst Chris Pierce reiterates Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) with a Buy and announces $66 price target.

Reiteration

BLBD

Needham Reiterates Buy on Blue Bird, Announces $66 Price Target

<ul>
<li>MariTide Demonstrated up to ~20% Average Weight Loss at 52 Weeks Without a Weight Loss Plateau in People Living With Obesity or Overweight</li>
<li>MariTide is the First Obesity Treatment With Monthly or Less Frequent Dosing to Demonstrate Safe and Effective Weight Loss in a Phase 2 Study</li>
<li>In People With Type 2 Diabetes Living With Obesity or Overweight MariTide Demonstrated up to ~17% Average Weight Loss Without a Weight Loss Plateau and Lowered Average HbA1c by up to 2.2 Percentage Points at 52 Weeks</li>
<li>MariTide Delivered Substantial Improvements Across Cardiometabolic Parameters</li>
<li>Amgen Announces "MARITIME," a Phase 3 Clinical Development Program in Obesity and Obesity-Related Conditions</li>
</ul>

Biotech

Health Care

General

AMGN

Amgen Announced Data At 52 Weeks In Phase 2 Study With MariTide (Maridebart Cafraglutide, Formerly AMG 133) Subcutaneously Administered Monthly Or Less Frequently, Showing Up To ~20% Average Weight Loss At Week 52 Without A Weight Loss Plateau

UBS analyst Thomas Wadewitz assumes United Airlines Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) with a Buy rating and announces Price Target of $139.

UBS Assumes United Airlines Holdings at Buy, Announces Price Target of $139

Kohl's Sees FY24 EPS Of $1.20-$1.50 (Prior View: $1.75-$2.25); Projects Net Sales Decrease Of (7)%-(8)%

<ul>
<li>- Upon closing, Arrowhead will receive $825 million immediately, including an upfront payment and an equity investment at a 35% premium, and will receive an additional $250 million paid over five years</li>
<li>- Arrowhead has potential to receive an additional $300 million in near-term clinical trial enrollment-related milestone payments and is eligible for future potential milestone payments up to $10 billion and royalties on sales</li>
<li>- Sarepta to receive investigational treatments that leverage Arrowhead's leading Targeted RNAi Molecule platform</li>
</ul>

ARRW

SRPT

Arrowhead Pharmaceuticals And Sarepta Therapeutics Enter Global License And Collaboration Deal For Genetic Disease Programs

Qualcomm Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>) <a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">interest in acquiring</a> Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) is reportedly waning due to the "complexities" involved.
What Happened: The challenges of executing such a deal with Intel have cooled Qualcomm&#8217;s enthusiasm, <a href="https://www.bloomberg.com/news/articles/2024-11-26/qualcomm-s-takeover-interest-in-intel-is-said-to-cool">Bloomberg</a> reported.
In September, reports suggested that&nbsp;Qualcomm approached&nbsp;Intel for a potential takeover, which would have been a significant merger in the tech sector.
Qualcomm might still consider purchasing parts of Intel or revisiting the idea of a full acquisition in the future.
This comes after Qualcomm outlined its strategy last week to diversify its business, aiming to boost annual revenue by $22 billion by 2029. CEO Cristiano Amon stated in an interview that no major acquisition is currently deemed necessary to achieve this target.
Qualcomm and Intel did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment. 
See Also: <a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report">Intel&#8217;s Federal Chips Grant Shrinks Below $8B As Biden Administration Recalibrates CHIPS Act Funding: Report</a>
Intel, once a leader in the chip industry, has faced setbacks, losing ground in the AI chip market.
In August, Intel&nbsp;announced a <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168042/intels-10b-cost-cut-seen-as-necessary-but-not-enough-for-competitive-edge-analyst">$10 billion cost-cutting&nbsp;initiative</a>, including workforce reductions and dividend suspension. Analysts have expressed skepticism about the potential deal, citing risks and financial implications for Qualcomm.
Subscribe to the&nbsp;<a href="https://bztechtrends.beehiiv.com/subscribe" target="_blank" rel="noreferrer noopener">Benzinga Tech Trends newsletter</a>&nbsp;to get all the latest tech developments delivered to your inbox.
Why It Matters: The potential acquisition of Intel by Qualcomm has been a topic of interest since September, when&nbsp;<a href="https://www.benzinga.com/news/24/09/40968128/qualcomm-reportedly-eyes-potential-takeover-of-intel-amid-60-stock-decline-but-antitrust-concerns-lo">Qualcomm reportedly considered the takeover</a>&nbsp;amid Intel&#8217;s 60% stock decline.
However, antitrust concerns have posed significant hurdles. Furthermore,&nbsp;<a href="https://www.benzinga.com/m-a/24/09/40983591/qualcomm-takeover-of-intel-is-logically-unlikely-in-face-of-regulatory-challenges-analyst-says">analysts have expressed doubts</a>&nbsp;about the feasibility of such a merger, citing regulatory challenges.
Adding to Intel&#8217;s challenges, the company is set to <a href="https://www.benzinga.com/24/11/42157390/intels-federal-chips-grant-shrinks-below-8b-as-biden-administration-recalibrates-chips-act-funding-report">receive less than $8 billion</a> in federal CHIPS Act funding, a reduction from the $8.5 billion initially planned. This funding cut comes as Intel struggles to meet its revenue targets with its Gaudi AI chips, as noted by CEO Pat Gelsinger during a third-quarter earnings call. The uptake of these chips has been <a href="https://www.benzinga.com/markets/equities/24/11/41686435/intel-says-it-wont-even-make-500m-from-gaudi-ai-chips-in-2024-despite-nvidia-minting-billions-ce">slower than expected</a>, impacting Intel&#8217;s financial outlook.
Price Action: Qualcomm stock gained 1.3% on Monday to close at $158.82, while Intel's stock rose 1.5% to close at $24.87. Year-to-date, Qualcomm shares are up 13.3%, while Intel's shares are down 48%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Consumer Tech coverage by&nbsp;<a href="https://www.benzinga.com/topic/consumer-tech" target="_blank" rel="noreferrer noopener">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42156373/marc-benioff-warns-were-near-the-upper-limits-of-llms-the-future-of-ai-lies-in-autonomous-agents-not-bots-like-chatgpt?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Marc Benioff Says The Future Of AI Not In Bots Like ChatGPT But In Autonomous Agents</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Markets

INTC

QCOM

Qualcomm's Interest In Taking Over Intel Wanes Due To 'Complexities' Involved: Report

UBS analyst Thomas Wadewitz assumes Alaska Air Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) with a Buy rating and announces Price Target of $72.

UBS Assumes Alaska Air Gr at Buy, Announces Price Target of $72

Guidance

BURL

Burlington Stores Expects Q4 Total Sales To Increase 5% To 7%; Comparable Store Sales To Increase 0% To 2%; Adjusted EPS Of $3.55 - $3.75 (Est $3.77)

MediWound (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDWD#NASDAQ">MDWD</a>) reported quarterly losses of $(0.98) per share which missed the analyst consensus estimate of $(0.45) by 117.78 percent. The company reported quarterly sales of $4.36 million which missed the analyst consensus estimate of $6.01 million by 27.49 percent. This is a 8.81 percent decrease over sales of $4.78 million the same period last year.

MDWD

MediWound Q3 2024 GAAP EPS $(0.98) Misses $(0.45) Estimate, Sales $4.36M Miss $6.01M Estimate

Outlook for the First Quarter of Fiscal Year 2025
For the first quarter of fiscal 2025, we are forecasting revenue of $2.35 billion, +/- $100 million. At the midpoint of this revenue outlook, we expect reported operating margin of approximately 22.0%, +/- 130 bps, and adjusted operating margin of approximately 40.0%, +/- 100 bps. We are planning for reported EPS to be $0.80, +/- $0.10, and adjusted EPS to be $1.53, +/- $0.10.&nbsp;&nbsp;

Analog Devices Sees Q1 Adj. EPS $1.43-$1.63 vs $1.56 Est., Revenue $2.25B-$2.45B vs $2.34B Est.

Matt Bilunas, Best Buy CFO, said "At the same time, we are maintaining our full year non-GAAP operating income rate of 4.1% to 4.2%, which represents slight expansion compared to FY24 on a 52-week basis."
Comparable sales1 of (3.5%) to (2.5%), which compares to prior guidance of (3.0%) to (1.5%).
&nbsp;

Best Buy Cuts FY25 Revenue Outlook From $41.3B - $41.9B To $41.1B - $41.5B, Est $41.592B; Revises Adj EPS Outlook From $6.10 - $6.35 To $6.10 - $6.25 (Est $6.25)

Needham analyst Mayank Tandon reiterates PAR Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAR#NYSE">PAR</a>) with a Buy and announces $90 price target.

Needham Reiterates Buy on PAR Technology, Announces $90 Price Target

Outlook
For fiscal 2025, the Company reiterates its full year revenue guidance of £650 million to £670 million and adjusted EBITDA guidance of £145 million to £160 million. The club remains committed to, and in compliance with, both the Premier League's Profit and Sustainability Rules and UEFA's Financial Fair Play Regulations.

MANU

Manchester United Reiterates 2025 Revenue Guidance Of £650M-£670M And Adjusted EBITDA Guidance Of £145M-£160M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics reported promising results from its Phase 2 SPRING trial for CM-101, a p...

Chemomab's Positive Trial Results Boost Investor Confidence

Chemomab Therapeutics GAAP EPS of -$0.01 beats by $0.05

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Chemomab Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmmb-stock-quote/">CMMB</a>) just reported results for the second quarter of 2024.<ul><li>Chemomab Therapeutics reported earnings per share of -26 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/cmmb-stock-earnings-chemomab-therapeutics-for-q2-of-2024/">CMMB Stock Earnings: Chemomab Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Roth MKM analyst Jason Wittes maintained a Buy rating on Chemomab Therapeutics (CMMB – Research Report) today and set a price target of $9.00. The ...

Roth MKM Sticks to Their Buy Rating for Chemomab Therapeutics (CMMB)

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on CMMB stock, giving a Buy rating today. Michael Okunewitch has given h...

Chemomab Therapeutics: Promising Clinical Progress and Strategic Regulatory Pathways Support Buy Rating

Chemomab Therapeutics (CMMB) has released an update. Chemomab Therapeutics has announced that its shareholders approved a proposal to grant 126,848...

Chemomab Therapeutics Aligns Leadership Incentives with Shareholders

Chemomab Therapeutics (CMMB) announced that data from its Phase 2 SPRING trial in patients with primary sclerosing cholangitis was presented at the...

Chemomab highlights clincial activity of CM-101 at The Liver Meeting 2024

CMMB

Press Releases

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Financing

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Present at September 2024 Investor Conferences

Chemomab Therapeutics to Present at October 2024 Investor Conferences

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Comments

Chemomab Therapeutics

Chemomab Therapeutics (CMMB) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO